This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kittleson, M. Articles by Stevenson, L. W. Search for Related Content PubMed PubMed Citation Articles by Kittleson, M. Articles by Stevenson, L. W.

CLINICAL RESEARCH: HEART FAILURE

Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality

^* Departments of Medicine and Cardiology, Brigham and Women’s Hospital, Boston, Massachusetts, USA

Manuscript received October 30, 2002; revised manuscript received January 17, 2003, accepted January 24, 2003.

^* Reprint requests and correspondence: Dr. Lynne Warner Stevenson, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA.
lstevenson{at}partners.org

OBJECTIVES: This study examined the hypothesis that patients who develop angiotensin-converting enzyme inhibitor intolerance attributable to circulatory-renal limitations (CRLimit) have more severe underlying disease and worse outcome.

BACKGROUND: Although the renin-angiotensin system contributes to the progression of heart failure (HF), it also supports the failing circulation. Patients with the most severe disease may not tolerate inhibition of this system.

METHODS: Consecutive inpatient admissions to the cardiomyopathy service of the Brigham and Women’s Hospital between 2000 and 2002 were reviewed retrospectively for initial profiles, discharge medications, and documented reasons for discontinuation of angiotensin-converting enzyme inhibitors. Outcomes of death and transplantation were determined.

RESULTS: Of the 259 patients, 86 were not on an angiotensin-converting enzyme inhibitor at discharge. Circulatory-renal limitations of symptomatic hypotension, progressive renal dysfunction, or hyperkalemia were documented in 60 patients (23%); other adverse effects, including cough, in 24 patients; and absent reasons in 2 patients. Compared with patients on angiotensin-converting enzyme inhibitors, patients with CRLimit were older (60 vs. 55 years; p = 0.006), with longer history of HF (5 vs. 2 years; p = 0.009), lower systolic blood pressure (104 vs. 110 mm Hg; p = 0.05), lower sodium (135 vs. 138 mEql/l; p = 0.002), and higher initial creatinine (2.5 vs. 1.2 mg/dl; p = 0.0001). Mortality was 57% in patients with CRLimit and 22% in the patients on angiotensin-converting enzyme inhibitors during a median 8.5-month follow-up (p = 0.0001).

CONCLUSIONS: Development of CRLimit to angiotensin-converting enzyme inhibitor intolerance identifies patients with severe disease who are likely to die during the next year. New treatment strategies should be targeted to this population.

Abbreviations and Acronyms   CRLimit   circulatory-renal limitations   HF   heart failure   LVAD   left ventricular assist device   NYHA   New York Heart Association   SBP   systolic blood pressure

This article has been cited by other articles:

				M. Metra, E. Eichhorn, W. T. Abraham, J. Linseman, M. Bohm, R. Corbalan, D. DeMets, T. De Marco, U. Elkayam, M. Gerber, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials Eur. Heart J., August 22, 2009; (2009) ehp338v1. [Abstract] [Full Text] [PDF]

				M. M. Givertz Therapeutic Strategies in Heart Failure Circulation, July 22, 2008; 118(4): e76 - e77. [Full Text] [PDF]

				J. I. Iglesias, L. DePalma, D. Hom, M. Antoniotti, S. Ayoub, and J. S. Levine Predictors of mortality in adult patients with congestive heart failure receiving nesiritide Retrospective analysis showing a potential adverse interaction between neseritide and acute renal dysfunction Nephrol. Dial. Transplant., January 1, 2008; 23(1): 144 - 153. [Abstract] [Full Text] [PDF]

				P. J. Hauptman, S. J. Goodlin, M. Lopatin, M. R. Costanzo, G. C. Fonarow, C. W. Yancy, and for the ADHERE Scientific Advisory Committee and A Characteristics of Patients Hospitalized With Acute Decompensated Heart Failure Who Are Referred for Hospice Care Arch Intern Med, October 8, 2007; 167(18): 1990 - 1997. [Abstract] [Full Text] [PDF]

				M. Metra, P. Ponikowski, K. Dickstein, J. J.V. McMurray, A. Gavazzi, C.-H. Bergh, A. G. Fraser, T. Jaarsma, A. Pitsis, P. Mohacsi, et al. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, June 1, 2007; 9(6-7): 684 - 694. [Abstract] [Full Text] [PDF]

				J. Iglesias, D. Hom, M. Antoniotti, S. Ayoub, and J. S. Levine Predictors of worsening renal function in adult patients with congestive heart failure receiving recombinant human B-type brain natriuretic peptide (nesiritide) Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3458 - 3465. [Abstract] [Full Text] [PDF]

				F. E. Marchlinski and M. Jessup Timing the Implantation of Implantable Cardioverter-Defibrillators in Patients With Nonischemic Cardiomyopathy J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2483 - 2485. [Full Text] [PDF]

				P. Ponikowski Rationale and design of CIBIS III Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C35 - C42. [Abstract] [Full Text] [PDF]

				M. R. Costanzo, M. Saltzberg, J. O'Sullivan, and P. Sobotka Early Ultrafiltration in Patients With Decompensated Heart Failure and Diuretic Resistance J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2047 - 2051. [Abstract] [Full Text] [PDF]

				L. W. Stevenson and P. Shekar Ventricular Assist Devices for Durable Support Circulation, August 30, 2005; 112(9): e111 - e115. [Full Text] [PDF]

				M. M. Kittleson, K. M. Minhas, R. A. Irizarry, S. Q. Ye, G. Edness, E. Breton, J. V. Conte, G. Tomaselli, J. G. N. Garcia, and J. M. Hare Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure Physiol Genomics, May 11, 2005; 21(3): 299 - 307. [Abstract] [Full Text] [PDF]

				J. R. Teerlink and B. M. Massie Nesiritide and Worsening of Renal Function: The Emperor's New Clothes? Circulation, March 29, 2005; 111(12): 1459 - 1461. [Full Text] [PDF]

				L. W. Stevenson Design of therapy for advanced heart failure Eur J Heart Fail, March 16, 2005; 7(3): 323 - 331. [Abstract] [Full Text] [PDF]

				J. J.V. McMurray and M. A. Pfeffer The year in heart failure J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2398 - 2405. [Full Text] [PDF]

				M. M. Kittleson, S. Q. Ye, R. A. Irizarry, K. M. Minhas, G. Edness, J. V. Conte, G. Parmigiani, L. W. Miller, Y. Chen, J. L. Hall, et al. Identification of a Gene Expression Profile That Differentiates Between Ischemic and Nonischemic Cardiomyopathy Circulation, November 30, 2004; 110(22): 3444 - 3451. [Abstract] [Full Text] [PDF]

				M. G. Shlipak and B. M. Massie The Clinical Challenge of Cardiorenal Syndrome Circulation, September 21, 2004; 110(12): 1514 - 1517. [Full Text] [PDF]

				L. W. Stevenson, L. W. Miller, P. Desvigne-Nickens, D. D. Ascheim, M. K. Parides, D. G. Renlund, R. M. Oren, S. K. Krueger, M. R. Costanzo, L. S. Wann, et al. Left Ventricular Assist Device as Destination for Patients Undergoing Intravenous Inotropic Therapy: A Subset Analysis From REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure) Circulation, August 24, 2004; 110(8): 975 - 981. [Abstract] [Full Text] [PDF]

				L. W. Stevenson and E. A. Rose Left Ventricular Assist Devices: Bridges to Transplantation, Recovery, and Destination for Whom? Circulation, December 23, 2003; 108(25): 3059 - 3063. [Full Text] [PDF]